Avoiding Drug Resistance in HIV Reverse Transcriptase
Open accessThe DOI matches its Crossref record; 305 of the 305 references it cites were found in a registry or an index.
Abstract
HIV reverse transcriptase (RT) is an enzyme that plays a major role in the replication cycle of HIV and has been a key target of anti-HIV drug development efforts. Because of the high genetic diversity of the virus, mutations in RT can impart resistance to various RT inhibitors. As the prevalence of drug resistance mutations is on the rise, it is necessary to design strategies that will lead to drugs less susceptible to resistance. Here we provide an in-depth review of HIV reverse transcriptase, current RT inhibitors, novel RT inhibitors, and mechanisms of drug resistance. We also present novel strategies that can be useful to overcome RT's ability to escape therapies through drug resistance. While resistance may not be completely avoidable, designing drugs based on the strategies and principles discussed in this review could decrease the prevalence of drug resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Resistance to them mainly arises from the high error rate of HIV reverse transcriptase (RT) during replication. The key resistance mechanisms involve either excision, where a mutated RT removes an incorporated NRTI, or discrimination, where mutations alter the dNTP-binding pocket to selectively block NRTI-triphosphate incorporation (4, 40).”
From Research progress on HIV-1 structural proteins and antiviral therapies (2026) · cites this paper as [40]
The cited source says what the claim attributes to it.
In the citing paper
“NNRTIs inhibit HIV-1 reverse transcriptase (RT) by binding to a specific, non-catalytic hydrophobic pocket known as the non-nucleoside inhibitor binding pocket (NNIBP). This binding site is located approximately 10 Å from the polymerase active site. The interaction induces conformational changes in RT that disrupt its enzymatic function, thereby inhibiting viral DNA synthesis (40, 45).”
From Research progress on HIV-1 structural proteins and antiviral therapies (2026) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
Ho, D. D., Neumann, A. U., Perelson, A. S., Chen, W., Leonard, J. M., & Markowitz, M. (1995) · Nature · doi:10.1038/373123a0 · Cited by 4,267
HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time
Perelson, A. S., Neumann, A. U., Markowitz, M., Leonard, J. M., & Ho, D. D. (1996) · Science · doi:10.1126/science.271.5255.1582 · Cited by 3,531
Viral dynamics in human immunodeficiency virus type 1 infection
Wei, X., Ghosh, S. K., Taylor, M. E., Johnson, V. A., Emini, E. A., Deutsch, P., Lifson, J. D., Bonhoeffer, S., Nowak, M. A., Hahn, B. H., et al. (1995) · Nature · doi:10.1038/373117a0 · Cited by 3,260
Computational protein–ligand docking and virtual drug screening with the AutoDock suite
Forli, S., Huey, R., Pique, M. E., Sanner, M. F., Goodsell, D. S., & Olson, A. J. (2016) · Nature Protocols · doi:10.1038/nprot.2016.051 · Cited by 2,811
Complete nucleotide sequence of the AIDS virus, HTLV-III
Ratner, L., Haseltine, W., Patarca, R., Livak, K. J., Starcich, B., Josephs, S. F., Doran, E. R., Rafalski, J. A., Whitehorn, E. A., Baumeister, K., et al. (1985) · Nature · doi:10.1038/313277a0 · Cited by 2,245
Computational Methods in Drug Discovery
Sliwoski, G., Kothiwale, S., Meiler, J., & Lowe, E. W. (2014) · Pharmacological Reviews · doi:10.1124/pr.112.007336 · Cited by 2,160
HIV Population Dynamics in Vivo: Implications for Genetic Variation, Pathogenesis, and Therapy
Coffin, J. M. (1995) · Science · doi:10.1126/science.7824947 · Cited by 1,981
Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor
Kohlstaedt, L. A., Wang, J., Friedman, J. M., Rice, P. A., & Steitz, T. A. (1992) · Science · doi:10.1126/science.1377403 · Cited by 1,914
Keele, B. F., Giorgi, E. E., Salazar-Gonzalez, J. F., Decker, J. M., Pham, K. T., Salazar, M. G., Sun, C., Grayson, T., Wang, S., Li, H., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802203105 · Cited by 1,912
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
Research works printed but not linked: 8
- Vogt V., 1997, Retroviruses
- Telesnitsky A., 1997, Retroviruses
- Volberding P., 2002, AIDS Read., 12, 349
- D’Aquila R. T., 2003, Top HIV Med., 11, 92
- Kirby K. A., 2011, Cell. Mol. Biol., 57, 40
- Grobler, J. A.; Fillgrove, K.; Hazuda, D.; Huang, Q.; Lai, M. T.; Matthews, R. P.; Rudd, D. J.; Vargo, R. MK-8591 potency and PK provide high inhibitory quotients at low doses QD and QW. In Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, WA , 2019; 481, http://www.croiconference.org/sessions/mk-8591-potency-and-pk-provide-high-inhibitory-quotients-low-doses-qd-and-qw (accessed 2020-07-13).
- Bekker, L-G.; Li, S. S.; Tolly, B.; Marzinke, M. A.; Mgodi, N.; Justman, J. E.; Swaminathan, S.; Adeyeye, A.; Farrior, J. H.; Sista, N. Hptn 076:Tmc278 ls safe, tolarable, and acceptable for HIV preexposure prophylaxis. In Proceedings of the Conference on Retroviruses and Opportunistic Infections, Seattle, WA , 2017.
- 2011, Janssen Products
Cited by
Recent Advances in Pyrimidine-Based Drugs
Nammalwar, B., & Bunce, R. A. (2024) · Pharmaceuticals · doi:10.3390/ph17010104 · Cited by 192
Approved HIV reverse transcriptase inhibitors in the past decade
Li, G., Wang, Y., & Clercq, E. D. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.11.009 · Cited by 144
Xue, Y., Liu, C., Andrews, G., Wang, J., & Ge, Y. (2022) · Nano Convergence · doi:10.1186/s40580-022-00307-9 · Cited by 115
HIV drug resistance in the era of contemporary antiretroviral therapy: A clinical perspective
Carr, A., Mackie, N., Paredes, R., & Ruxrungtham, K. (2023) · Antiviral Therapy · doi:10.1177/13596535231201162 · Cited by 89
“1,17,18 The high replication rate, error-prone reverse transcription and high recombination rate of HIV give rise to a genetically diverse, heterogeneous virus population that is distributed as a quasispecies.”
BackgroundInfluentialWang, Z., Cherukupalli, S., Xie, M., Wang, W., Jiang, X., Jia, R., Pannecouque, C. C., Clercq, E. D., Kang, D., Zhan, P., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01758 · Cited by 78
Sever, B., Otsuka, M., Fujita, M., & Ciftci, H. I. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073659 · Cited by 77
HIV nucleoside reverse transcriptase inhibitors
Amblard, F., Patel, D. J., Michailidis, E., Coats, S. J., Kasthuri, M., Biteau, N., Tber, Z., Ehteshami, M., & Schinazi, R. F. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114554 · Cited by 67
Du, S., Hu, X., Menéndez‐Arias, L., Zhan, P., & Liu, X. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101053 · Cited by 61
Singh, A. K., & Das, K. (2022) · Viruses · doi:10.3390/v14051027 · Cited by 58
“Several mutations have been characterized which allow RT to discriminate between an NRTI-TP and a natural dNTP (reviewed in References [48,51,52,66]).”
BackgroundKang, D., Ruiz, F. X., Sun, Y., Feng, D., Jing, L., Wang, Z., Zhang, T., Gao, S., Sun, L., Clercq, E. D., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00268 · Cited by 58
“At first, the commercially available material 2,4 dichloropyrimidine (5) was reacted with 4-hydroxy-3,5-dimethylbenzonitrile at room temperature, affording intermediate 6, which generated compound 7 with tert-butyl 4 aminopiperidine-1-carboxylate at 120°C via nucleophilic reaction.”
MethodDrug Resistance: An Incessant Fight against Evolutionary Strategies of Survival
Ramos‐Martín, F., & D’Amelio, N. (2023) · Microbiology Research · doi:10.3390/microbiolres14020037 · Cited by 56
Lau, C., Adan, M. A., & Maldarelli, F. M. (2021) · Viruses · doi:10.3390/v13122512 · Cited by 49
Antiviral drug discovery and development: challenges and future directions
Du, S., Hu, X., Li, P., Xu, S., Kim, M., Liu, X., & Zhan, P. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02539-7 · Cited by 51
“356 Currently, this hypothesis is extensively employed in the design of HIV protease inhibitors.”
Zhang, K., Zhang, Y., Li, M., Pannecouque, C. C., Clercq, E. D., Wang, S., & Chen, F. (2024) · Medicinal Research Reviews · doi:10.1002/med.22080 · Cited by 35
Jiang, X., Huang, B., Rumrill, S., Pople, D., Zalloum, W. A., Kang, D., Zhao, F., Ji, X., Gao, Z., Hu, L., et al. (2023) · Communications Chemistry · doi:10.1038/s42004-023-00888-4 · Cited by 35
Wang, Z., Zalloum, W. A., Wang, W., Jiang, X., Clercq, E. D., Pannecouque, C. C., Kang, D., Zhan, P., & Liu, X. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01015 · Cited by 28
Kang, D., Sun, Y., Feng, D., Gao, S., Wang, Z., Jing, L., Zhang, T., Jiang, X., Lin, H., Clercq, E. D., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01885 · Cited by 27
Ding, L., Pannecouque, C. C., Clercq, E. D., Zhuang, C., & Chen, F. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01676 · Cited by 26
Precursors of Viral Proteases as Distinct Drug Targets
Majerová, T., & Novotný, P. (2021) · Viruses · doi:10.3390/v13101981 · Cited by 28
Wang, Z., Sharma, P. P., Rathi, B., Xie, M., Clercq, E. D., Pannecouque, C. C., Kang, D., Zhan, P., & Liu, X. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00275 · Cited by 26
Cilento, M. E., Reeve, A. B., Michailidis, E., Ilina, T. V., Nagy, E., Mitsuya, H., Parniak, M. A., Tedbury, P. R., & Sarafianos, S. G. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01167-21 · Cited by 24
Self-citationWhich ‘imperfect vaccines’ encourage the evolution of higher virulence?
Bull, J. J., & Antia, R. (2022) · Evolution Medicine and Public Health · doi:10.1093/emph/eoac015 · Cited by 23
Zhao, F., Zhang, H., Xie, M., Meng, B., Liu, N., Dun, C., Qin, Y., Gao, S., Clercq, E. D., Pannecouque, C. C., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01875 · Cited by 23
Nanoparticle‑based antiviral strategies to combat the influenza virus (Review)
Ríos-Ibarra, C. P., Salinas-Santander, M. A., Orozco-Nunnelly, D. A., & Madrigal, J. B. (2024) · Biomedical Reports · doi:10.3892/br.2024.1753 · Cited by 21
Singh, A. K., Wijngaert, B. D., Bijnens, M., Uyttersprot, K., Nguyen, H. V., Martinez, S. E., Schols, D., Herdewijn, P. A., Pannecouque, C. C., Arnold, E., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2203660119 · Cited by 20
Sun, Y., Feng, D., Zhou, Z., Zhang, T., Clercq, E. D., Pannecouque, C. C., Kang, D., Zhan, P., & Liu, X. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117484 · Cited by 20
Current medicinal chemistry strategies in the discovery of novel HIV-1 ribonuclease H inhibitors
Zhang, L., Wei, F., Zhang, J., Liu, C., López‐Carrobles, N., Liu, X., Menéndez‐Arias, L., & Zhan, P. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114760 · Cited by 20
Azzman, N., Gill, M. S. A., Hassan, S. S., Christ, F., Debyser, Z., Mohamed, W. A. S., & Ahemad, N. (2024) · Reviews in Medical Virology · doi:10.1002/rmv.2529 · Cited by 24
“128 In Phase 2a research, Islatravir (ISL) was studied as a monthly oral PrEP and an implant with the potential for once ‐ yearly implanted administration.”
BackgroundSuhandi, C., Wilar, G., Narsa, A. C., Mohammed, A. F. A., El‐Rayyes, A., Muchtaridi, M., Shamsuddin, S., Safuan, S., & Wathoni, N. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s478388 · Cited by 20
Sun, Y., Zhou, Z., Feng, D., Jing, L., Zhao, F., Wang, Z., Zhang, T., Lin, H., Song, H., Clercq, E. D., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00576 · Cited by 18
Kang, D., Urhan, Ç., Wei, F., Frutos-Beltrán, E., Sun, L., Álvarez, M., Feng, D., Tao, Y., Pannecouque, C. C., Clercq, E. D., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113769 · Cited by 19
Gao, S., Song, L., Cheng, Y., Zhao, F., Kang, D., Song, S. L., Yang, M., Ye, B., Zhao, W., Ya-jie Tang, A., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.01.003 · Cited by 17
Synthetic approaches and application of clinically approved small-molecule Anti-HIV drugs: An update
Sun, L., Nie, P., Li, L., Herdewijn, P. A., & Wang, Y. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115847 · Cited by 16
Wang, Z., Zhang, H., Gao, Z., Sang, Z., Clercq, E. D., Pannecouque, C. C., Kang, D., Zhan, P., & Liu, X. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.11.023 · Cited by 17
“All the target compounds were first screened for their anti-HIV activitiesagainst the WT (IIIB) and double-mutant K103N þ Y181C (RES056) HIV-1 strains.”
BackgroundInfluentialVoloshin, Y. Z. (2025) · Chemistry - An Asian Journal · doi:10.1002/asia.202401842 · Cited by 14
Feng, D., Lin, H., Jiang, L., Dai, J., Zhang, X., Zhou, Z., Sun, Y., Wang, Z., Clercq, E. D., Pannecouque, C. C., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114957 · Cited by 14
State of the ART (antiretroviral therapy): Long-acting HIV-1 therapeutics
Ravichandran, S., McFadden, W. M., Snyder, A. A., & Sarafianos, S. G. (2024) · Global Health & Medicine · doi:10.35772/ghm.2024.01049 · Cited by 15
Self-citationMeng, B., Zhuo, Z., Yu, H., Tao, S., Chen, Z., Clercq, E. D., Pannecouque, C. C., Kang, D., Zhan, P., & Liu, X. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2023.108827 · Cited by 10
Jing, L., Wu, G., Zhao, F., Jiang, X., Liu, N., Feng, D., Sun, Y., Zhang, T., Clercq, E. D., Pannecouque, C. C., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116772 · Cited by 9
Xie, X., Zheng, Y.-G., Chen, H., Li, J., Luo, R., Chen, L., Zheng, C., Zhang, S., Peng, P., Ma, D., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01383 · Cited by 9
Kim, M., Yu, K. L., Han, R., Lee, Y., Oh, K., & You, J. C. (2023) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.3c00166 · Cited by 8
Sun, Y., Zhou, Z., Shi, Z., Zhao, F., Xie, M., Zhuo, Z., Clercq, E. D., Pannecouque, C. C., Kang, D., Zhan, P., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.03.021 · Cited by 8
Xie, M., Wang, Z., Zhao, F., Ye, L., Zhuo, Z., Li, X., Clercq, E. D., Pannecouque, C. C., Zhan, P., Liu, X., et al. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29502 · Cited by 8
“8,9 However, the lack of intrinsic exonucleolytic proofreading during RT reverse transcription of HIV ‐ 1 lead to its low genetic barrier, resulting in the rapid development of drug resistance.”
BackgroundZhang, L., Wei, F., Borrego, D., Zhao, F., del Río, J. M., Frutos-Beltrán, E., Zhang, J., Xu, S., López‐Carrobles, N., Gao, S., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114563 · Cited by 8
Wang, Z., Rumrill, S., Kang, D., Guma, S. D., Feng, D., De Clercq, E., Pannecouque, C., Chen, C. H., Arnold, E., Ruiz, F. X., et al. (2025) · Science Advances · doi:10.1126/sciadv.adt8916 · Cited by 7
“High levels of resistance can be rapidly induced by a single–amino acid point mutation, as exemplified by the two most prevalent single mutants: K103N and Y181C ( 10 , 11 ).”
The role of HIV-1 polymorphism in the pathogenesis of the disease
Kuznetsova, A. I. (2023) · HIV Infection and Immunosuppressive Disorders · doi:10.22328/2077-9828-2023-15-3-26-37 · Cited by 7
Kang, D., Yang, J., Kong, L., Luo, R., Huang, X., Zhang, T., Ma, M., Feng, D., Wang, Z., Fang, H., et al. (2022) · Viruses · doi:10.3390/v14112390 · Cited by 7
“However, a variety of drug-resistant mutants (such as L100I, K101P/E, K103N/S, Y181C/I/V, Y188L/I/C/V, V106A/M, F227L, E138K/R, and G190A/S) have emerged clinically, due to the high gen tic diversity of HIV-1, and these mutations in RT can develop drug resistance to existing RT inhibitors [12].”
BackgroundFeng, D., Lin, H., Jiang, L., Wang, Z., Sun, Y., Zhou, Z., Clercq, E. D., Pannecouque, C. C., Kang, D., Zhan, P., et al. (2022) · Molecules · doi:10.3390/molecules27217538 · Cited by 7
Considerations for capsid-targeting antiretrovirals in pre-exposure prophylaxis
McFadden, W. M., Færch, M., Kirby, K. A., Dick, R. A., Torbett, B. E., & Sarafianos, S. G. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.01.013 · Cited by 7
Self-citationTargeting HIV-1 Reverse Transcriptase Using a Fragment-Based Approach
Mansouri, M., Rumrill, S., Dawson, S., Johnson, A., Pinson, J., Gunzburg, M. J., Latham, C. F., Barlow, Ν., Mbogo, G. W., Ellenberg, P. C., et al. (2023) · Molecules · doi:10.3390/molecules28073103 · Cited by 6
“Inhibition of WT RT DDDP activity was initially evaluat d by t sting three conc ntratio s of compound in two indepe nt assays using nevirapine (a FDA approved NNRTI) as the positive control [3].”
BackgroundMethodInfluentialNurjannah, N., Jayanti, S. D., Tanoerahardjo, F. S., Musyahadah, U. S. A., Sukowati, C. H. C., & Massi, M. N. (2024) · Current HIV/AIDS Reports · doi:10.1007/s11904-023-00687-5 · Cited by 5
Jiang, X., Zalloum, W. A., Gao, Z., Dai, J., Ji, X., Xie, M., Dong, G., Clercq, E. D., Huang, B., Pannecouque, C. C., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116941 · Cited by 5
Dai, J., Jiang, X., Gao, H., Huang, B., Clercq, E. D., Pannecouque, C. C., Du, S., Liu, X., & Zhan, P. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117033 · Cited by 4
Yu, K.-L., Shin, Y., Kim, D., Kim, J.-A., Kang, J.-E., Singh, P., Lee, K. W., Park, C. M., Kwon, H. S., Kim, S., et al. (2025) · Virology Journal · doi:10.1186/s12985-025-02680-3 · Cited by 4
“4C), whereas the hydrophobic residues V106 and V108, known to interact with DOR [44, 67] are not important for the BPPT activity to the extent they are for DOR.”
InfluentialEnhancing HIV Drug Resistance Prediction Using Bidirectional LSTM Neural Networks
Poojitha, D., Darak, T., Samaddar, U., S, V. C., Karthikeyan, B., & Korlepara, D. B. (2025) · Procedia Computer Science · doi:10.1016/j.procs.2025.04.549 · Cited by 4
Doravirine/islatravir for the treatment of HIV
Williams, V., & Cory, T. J. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2440000 · Cited by 4
Song, H., Xia, Y., Zhang, T., Dun, C., Meng, B., Clercq, E. D., Pannecouque, C. C., Kang, D., Zhan, P., & Liu, X. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115686 · Cited by 4
Ji, X., Jiang, X., Gao, H., Gao, Z., Clercq, E. D., Pannecouque, C. C., Kang, D., Zhan, P., & Liu, X. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02211 · Cited by 3
Gao, P., Song, S. L., Pannecouque, C. C., Clercq, E. D., Zhan, P., & Liu, X. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00469h · Cited by 3
Ji, X., Jiang, X., Gao, Z., Gao, H., Clercq, E. D., Pannecouque, C. C., Kang, D., Zhan, P., & Liu, X. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117787 · Cited by 3
Zhang, T., Zhou, Z., Zhao, F., Sang, Z., Clercq, E. D., Pannecouque, C. C., Kang, D., Zhan, P., & Liu, X. (2022) · Pharmaceuticals · doi:10.3390/ph15111438 · Cited by 3
Research progress on HIV-1 structural proteins and antiviral therapies
Wang, H., Yuan, J., & Wang, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1805597 · Cited by 2
Zhuo, Z., Wang, Z., Jing, L., Zhang, T., Ge, A., Zhou, Z., Liu, Y., Li, X., Clercq, E. D., Pannecouque, C. C., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25169028 · Cited by 2
Muchinta, E., & Chabala, F. W. (2025) · PLoS ONE · doi:10.1371/journal.pone.0330356 · Cited by 2
Structural biology of HIV-1 reverse transcriptase allosteric inhibitors for drug design
Zhou, Z., Sun, Y., Feng, D., Wang, Z., Zhao, F., Gao, S., Zhan, P., Kang, D., & Liu, X. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.11.007 · Cited by 3
“Since the residues of NNIBP are not directly involved in the polymerization process of RT, the NNIBP residues have little cost of mutation, while the potency of NNRTIs is reduced or even lost 20 .”
Zhang, Y.-X., Pannecouque, C. C., Clercq, E. D., Tramontano, E., Corona, A., Dettori, L., Tran, P., Li, X.-D., Su, S., Wang, S., et al. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.01.010 · Cited by 2
Electrochemical coupling of CO2 and phosphite for foscarnet synthesis
Wang, H., Duan, R., Wang, Y., Zhou, M., Zhao, W., Yang, J., Yin, Y., Zhang, S., Liu, S., Ling, Z., et al. (2026) · Nature Catalysis · doi:10.1038/s41929-026-01608-6 · Cited by 2
“Among them, the antiviral drug foscarnet (priced at ~US$13,561 ton −1 ), which functions as a viral DNA polymerase inhibitor, is clinically essential for treating herpesvirus infections and exhibits therapeutic potential against cytomegalovirus retinitis 4–7 .”
In silico approach for fighting human immunodeficiency virus: a drug repurposing strategy
Crisan, L., & Istrate, D. (2024) · Chemical Papers · doi:10.1007/s11696-024-03789-5 · Cited by 2
“While some people acquire resistance when infected, other patients may develop resistance over time, and ongoing efforts are being made to identify and develop new RT inhibitors that are effective in treating and preventing HIV-1 (Ding et al. 2021; Cilento et al. 2021).”
Kuznetsova, A. I., Munchak, I. M., Lebedev, A. V., Туманов, А. С., Kim, K. V., Antonova, A. A., Ozhmegova, E., Pronin, A. Y., Drobyshevskaya, E. V., Валерьевна, К. Е., et al. (2023) · Problems of Virology · doi:10.36233/0507-4088-161 · Cited by 2
Wang, Q., Kline, E. C., Gilligan-Steinberg, S. D., Lai, J. J., Hull, I. T., Olanrewaju, A. O., Panpradist, N., & Lutz, B. R. (2024) · medRxiv · doi:10.1101/2024.03.29.24305085 · Cited by 2
Wang, Z., Wang, W., Gao, Z., Gao, H., Clercq, E. D., Pannecouque, C. C., Chen, C., Kang, D., Zhan, P., & Liu, X. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29830 · Cited by 1
“14 Second ‐ generation NNRTIs also show significant loss of susceptibility to emerging mutants, such as the single ‐ mutant strains L100I for ETR, E138K for RPV, and the double ‐ mutant strain F227L/ V106A for DOR.”
Guerrero, J. F., Zimdars, L. L., Bruce, J. W., Becker, J. T., Evans, E. L., Torabi, S., Striker, R., Berry, S. M., & Sherer, N. M. (2025) · Journal of Virology · doi:10.1128/jvi.01579-24 · Cited by 1
The Discovery and Development of Islatravir (4′‐Ethynyl‐2‐fluoro‐2′‐deoxyadenosine [EFdA], MK‐8591)
Snyder, A. A., Wen, X., Michailidis, E., Kirby, K. A., Mitsuya, H., & Sarafianos, S. G. (2025) · Wiley eBooks · doi:10.1002/9783527845088.ch04 · Cited by 2
Self-citationZhang, T., Yang, Y., Li, X., Zhao, F., Zhuo, Z., Wang, L., Zhang, W., Clercq, E. D., Pannecouque, C. C., Zhan, P., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01102 · Cited by 1
Zhou, Z., Lin, Z., Jiang, W., Zhang, W., Zhao, F., Liang, Z., Clercq, E. D., Pannecouque, C. C., Zhan, P., Kang, D., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117992 · Cited by 1
Zhang, Y.-X., Pannecouque, C. C., Clercq, E. D., Tramontano, E., Corona, A., Dettori, L., Tran, P., Li, X.-D., Su, S., Wang, S., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02556 · Cited by 1
Clicking viruses—with chemistry toward mechanisms in infection
Greber, U. F. (2025) · Journal of Virology · doi:10.1128/jvi.00471-25 · Cited by 1
Role of Computational Modelling in Drug Discovery for HIV
Gomatam, A., Khan, A. A., Raikuvar, K., D'Costa, M., & Coutinho, E. C. (2023) · Challenges and advances in computational chemistry and physics · doi:10.1007/978-3-031-33871-7_6 · Cited by 1
Tenorio, A. M., Lerma, A. E. D. M. Z., Reyes, A. O., Galván, L. E. P., & Madrigal, J. B. (2023) · Journal of bioengineering and biomedicine research. · doi:10.70632/jbbr.7.3.2023.8-32
Kuznetsova, A. I., Antonova, A. A., Lebedev, A. V., Ozhmegova, E., Shlykova, A. V., Lapovok, I., & Galzitskaya, O. V. (2024) · Problems of Virology · doi:10.36233/0507-4088-272
Goffin, E., Torfs, L., Tsingis, F., Švestka, D., Erven, K., Uyttersprot, K., Heens, C., Wilms, S., Rozenski, J., Lescrinier, E., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117818
Zhou, Z., Guo, J., Li, X., Wu, J., Clercq, E. D., Pannecouque, C. C., Zhan, P., Kang, D., & Liu, X. (2025) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5c00519
Synthesis of aryl benzamides containing a pyrimidine moiety as possible HIV-1 NNRTIs
Mohasoa, L. C., Fernandes, M. A., Zimuwandeyi, M., & Bode, M. L. (2025) · ARKIVOC · doi:10.24820/ark.5550190.p012.434
Age, gender aspects of nervous system damage in hiv infection and modern treatment options
Yusupov, F. A., Токтосунович, Ы. И., & Yuldashev, A. A. (2025) · Clinical Medicine (Russian Journal) · doi:10.30629/0023-2149-2025-103-4-263-271 · Cited by 1
Qiu, J., Zhang, Y., Hu, M., Huang, Z., Han, Z., Wan, J., Wei, Y., Xie, J., Zhang, D., Luo, X., et al. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c01588
Liu, Y., Wang, R., Wang, H., & Liu, W. (2025) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.5c04843
Introduction to Drug Repurposing for Antiviral Therapy
Singh, H., Singh, B. K., Chauhan, K., Mehara, G., Singh, P. N. D., & Garg, S. S. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898811143125010003
Ontwikkeling en SAR verkenning van nieuwe doravirine- en catechol-afgeleide hybride NNRTIs
Goffin, E. (2025) · Lirias (KU Leuven)
McFadden, W. M., Kirby, K. A., Lorson, Z. C., Wang, L., Highland, C. M., Harvey, S. R., Brancato, S. G., Castaner, A. E., Du, H., Wysocki, V. H., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.19.712970
Self-citationMolecular basis of the interaction between HIV-1 integrase and viral RNA
Rocchi, C. (2022) · theses.fr (ABES) · doi:10.70675/56a488fez1f79z4d34z81d9z905314a2ca30
Aiko, B. G., Guariguata, L., Myemba, D. T., Bwire, G. M., Nyondo, G. G., Sangeda, R. Z., Killewo, J., Vandaele, N. J., & Decouttere, C. J. (2026) · BMC Public Health · doi:10.1186/s12889-026-27723-4
“ART typically consists of three different drugs chosen from one of the four main classes of anti-HIV drugs: nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), and integrase strand transfer inhibitors (INSTIs) [5].”
Snyder, A. A., Kaufman, I. L., MacQuillan, J., Slack, R. L., Kirby, K. A., Michailidis, E., & Sarafianos, S. G. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.08.730881
Self-citationLao, X., He, L., Li, Y., Zhang, H. X., Yu, F., Zhao, H., Liao, L., Li, D., Li, Y., Liang, X., et al. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110140
Beyond one drug–one target: AI-guided discovery of multi-target antiviral therapeutics
Gupta, V., Sharma, S., Abbot, V., Bhatia, R., Choudhary, N., & Kumar, D. (2026) · Frontiers in Virology · doi:10.3389/fviro.2026.1853552
Ali, H., Hashmi, M. A., Ajmal, N., Goraija, M. S., Rasool, N., Siddiqua, U. H., & Malik, A. (2026) · RSC Advances · doi:10.1039/d6ra04544h
“89,90 Although more than 50 structurally diverse classes of NNRTIs have been discovered in the past few decades, pyrimidine-based compounds (such as etravirine (ETR) and rilpivirine (RPV), which were approved in 2008 and 2011, respectively) continue to be a major focus in current optimization e ff…”
Cutting-edge developments in computer-aided anti-HIV drug design
Yang, W., Wang, Y., Feng, C., Tang, W., & Sun, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1873962
“Consequently, reverse transcriptase is regarded as a critical molecular target in the development of therapeutic agents aimed at combating HIV (70).”
Alqaaf, M., Mamun, M. A. A., Nasution, A. K., Islam, A. S. M. N., Supriyanti, R., Ono, N., Kanaya, S., & Altaf-Ul-Amin, M. (2026) · Pharmaceuticals · doi:10.3390/ph19101534
“The exceptionally high replication rate of HIV-1, coupled with its pronounced genetic variability, facilitates the rapid accumulation of resistance-associated mutations in key viral enzymes, such as reverse transcriptase, protease, and integrase, even under sustained drug pressure [5,6].”
Юсупов, Ф. А., Токтосунович, Ы. И., & Акбарович, Ю. А. (2025) · Clinical Medicine (Russian Journal)
Metadata
- Authors
- Cilento, M. E., Kirby, K. A., & Sarafianos, S. G.
- Affiliations
- Emory University (US)
- Corresponding author
- Sarafianos, Stefan G.
- Venue
- Chemical Reviews
- Publisher
- American Chemical Society (ACS)
- Published
- 2021-01-28
- Volume
- 121
- Issue
- 6
- Pages
- 3271-3296
- ISSN
- 0009-2665 (ISSN-L)
- 1520-6890
- PMC
- PMC8149104
- OpenAlex
- W3125954347
- Cited by
- 106
- References
- 305
- Citations by year
- 2026: 15 · 2025: 22 · 2024: 27 · 2023: 17 · 2022: 18 · 2021: 7
- FWCI
- 2.28
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- Chemical Reviews (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (R01 AI121315, R37 AI076119, U54 AI150472)
- National Institute of General Medical Sciences (R01 GM118012, T32 GM008367)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- HIV reverse transcriptase, drug resistance, reverse transcriptase inhibitors, resistance mutations, HIV drug development, antiretroviral therapy
- MeSH terms
- Humans, Models, Molecular, Mutation, Protein Binding, Protein Conformation, Structure-Activity Relationship, Virus Replication, Drug Design, Signal Transduction, HIV-1, HIV Infections, Reverse Transcriptase Inhibitors, Anti-HIV Agents, Drug Resistance, Viral, HIV Reverse Transcriptase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.